Evofem Biosciences, Inc.
EVFM- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001618835
No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EVFM, Q2 2026
No superinvestor reported holding EVFM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Evofem Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2024 (view filing)5:13 PM ET | Jan 12 | Same day | Zhang YanCFO | SSale | −104 | $0.0385 | −$4 | −100.0%0 after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Kamdar Kim P.Director | SSale | −10 | $0.62 | −$6.2 | −100.0%0 after | |
| May 31, 2022 (view filing)8:55 AM ET | May 27 | 4 days | Pelletier Saundra LChief Executive Officer | PPurchase | +141.0K | $0.3525 | +$49.7K | +147.3%236.7K after | |
| Dec 20, 2021 (view filing)4:20 PM ET | Dec 20 | Same day | Fitzpatrick Alexander AGeneral Counsel and Secretary | PPurchase | +25.0K | $0.389 | +$9.72K | +8.0%336.4K after | |
| Dec 20, 2021 (view filing)4:20 PM ET | Dec 20 | Same day | File Justin J.Chief Financial Officer | PPurchase | +40.6K | $0.37 | +$15.0K | +9.2%481.0K after | |
| Dec 20, 2021 (view filing)4:19 PM ET | Dec 20 | Same day | Pelletier Saundra LChief Executive Officer | PPurchase | +135.0K | $0.375 | +$50.6K | +15.9%985.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Evofem Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding EVFM in 13F filings for Q2 2026.